CYP2A6 and ERCC1 polymorphisms correlate with efficacy of S-1 plus cisplatin in metastatic gastric cancer patients

BACKGROUND: We evaluated the association between polymorphisms of cytochrome P450 2A6 (CYP2A6)/excision repair cross-complementation group 1 (ERCC1)/X-ray repair cross-complementing group 1(XRCC1) and treatment outcomes of metastatic gastric cancer (MGC) patients treated with S-1/cisplatin. METHODS:...

Descripción completa

Detalles Bibliográficos
Autores principales: Park, S R, Kong, S-Y, Nam, B-H, Choi, I J, Kim, C G, Lee, J Y, Cho, S J, Kim, Y W, Ryu, K W, Lee, J H, Rhee, J, Park, Y-I, Kim, N K
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2011
Materias:
Molecular Diagnostics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3068488/
https://www.ncbi.nlm.nih.gov/pubmed/21364592
http://dx.doi.org/10.1038/bjc.2011.24

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3068488/
https://www.ncbi.nlm.nih.gov/pubmed/21364592
http://dx.doi.org/10.1038/bjc.2011.24

Ejemplares similares